Why We Need to Rethink Ethnicity-Based Genetic Testing
By Shivani Nazareth,
US News & World Report
| 11. 07. 2016
A recent study noted racial bias in the genetic databases that are important to furthering research in precision medicine. The data is skewed toward a European Caucasian population, which makes it difficult to interpret genetic variants in minority groups. As the U.S. population increasingly diversifies, we need to challenge ourselves to do better. A good place to begin is pregnancy, when nearly every woman in the U.S. is offered genetic carrier screening.
Carrier screening is the practice of testing of both mom and dad for inherited conditions that may be passed along to their baby. A pregnant woman is typically offered screening – for one condition, a few conditions or a panel – based upon her self-reported ethnic category. As an example, black patients are offered screening for sickle cell disease, Southeast Asian patients for thalassemias and Ashkenazi Jewish patients for a panel that includes Canavan and Tay-Sachs disease, among others. This approach is based on a public health model that factors cost and the availability of a reliable test into the screening equation. In the past few...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...